Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8⁺T-cells despite immune checkpoint signaling

Abstract

These data may explain the failure of single-agent immune checkpoint inhibitors in the treatment of DLBCL. Accordingly, functional differences of CD8+ T-cells between FL and DLBCL may inform future therapeutic targeting strategies.